ARGX

Here is how argenex SE (ARGX) and Agilent Technologies (A) have performed compared to their sector so far this year.

I upgrade argenx to BUY with a $1,050 price target, citing sustained VYVGART growth, label expansion, and a strong balance sheet. VYVGART's commercial momentum is robust, with expanded indications, at-home administration, and a growing prescriber base supporting long-term growth. Pipeline optionality, notably empasiprubart and autoimmune myositis, provides meaningful upside not fully reflected in ARGX's current valuation.

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Forte Biosciences, Inc. (NasdaqCM: FBRX) to argenx SE (NasdaqGS: ARGX). Under the terms of the proposed transaction, shareholders of Forte will receive $77.00 in cash for each share of Forte that they own. KSF is seeking to determine whether this consideration and the process that led to it are adeq.

Forte Biosciences (NASDAQ:FBRX) shares surged about 40% to around $76 on Monday after argenx (NASDAQ:ARGX) announced an agreement to acquire the biotechnology company in a deal valued at approximately $2.2 billion. Under the terms of the agreement, argenx will acquire all outstanding Forte Biosciences shares for $77 per share in cash.

argenex NASDAQ: ARGX said it has agreed to acquire Forte Biosciences in a transaction valued at approximately $2.2 billion in equity value, adding FB102, an anti-CD122 antibody being developed for autoimmune diseases including vitiligo and celiac disease.

The deal to acquire the Nasdaq-listed Forte represents a 41% premium to its closing price on Friday.

Belgian-Dutch immunology company argenx ​will buy ‌Forte Biosciences to add experimental ​autoimmune drug ​FB102 to its portfolio, ⁠the company ​said on ​Monday.

Transaction builds on argenx's prior strategic investment in Forte Biosciences and reflects a disciplined approach to accessing novel biology that can fuel long-term growth FB102 Phase 1b studies in vitiligo and celiac disease validate CD122 biology and pipeline-in-a-product potential to address diseases with high unmet need that have lacked innovation Acquisition strengthens argenx's innovative immunology portfolio with the addition of a differentiated approach to targeting pathogenic T-cell and NK-cell activity through CD122 biology argenx will host an investor conference call today at 8:00 a.m. ET to discuss the transaction July 27, 2026 – 7:00 AM CET Amsterdam, the Netherlands and Dallas, Texas – argenx (Euronext & Nasdaq: ARGX), a global immunology innovation company, and Forte Biosciences, Inc. (Nasdaq: FBRX) today announced that the companies have entered into a definitive agreement under which argenx will acquire Forte Biosciences for $77 per share in cash, representing a total equity value of approximately $2.2 billion.

argenx delivered a Q2 marked by surging profitability, robust cash generation, and operational leverage from its autoimmune franchise. ARGX's efgartigimod franchise, especially in gMG, underpins a $50B+ enterprise value, with pipeline catalysts like empasiprubart in MMN on the horizon. With $3.6B in cash, minimal debt, and self-funded R&D, ARGX is well-positioned for continued innovation and pipeline expansion.

argenx SE (ARGX) Q2 2026 Earnings Call Transcript